Immunology Studies 免疫学研究, 2014, 2, 17-22Published Online May 2014 in Hans. /journal/is/10.12677/is.2014.22004Changes and Significance of Serum SolubleComplement Receptor 2 in Patients withPrimary Sjogren’s SyndromeNingning Li1, Yongli Zhang1*, Xiaofei Wang2, Yunhua Hou1, Xiaoyang Ying1,Chenchen Wang1, Ting Zhang1, Ying Liu1, Fang Wang31Affiliated Zhongshan Hospital of Dalian University, Dalian2Sheng Jing Hospital of China Medical University, Shenyang3The Central Hospital of Liaoyang, LiaoyangEmail: ning12161121@, *Zhangyongli8822@Received: Apr. 9th, 2014; revised: May 10th, 2014; accepted: May 15th, 2014Copyright © 2014 by authors and Hans Publishers Inc.This work is licensed under the Creative Commons Attribution International License (CC BY)./licenses/by/4.0/AbstractAim: Changes and significance of serum soluble complement receptor 2 (sCR2) in patients with primary Sjogren’s syndrome (pSS) are discussed. Methods: ELISA was developed for the deter- mination of sera sCR2 concentration in sera of 20 pSS patients and 20 healthy volunteers. Statis- tical analysis was performed by using SPSS software. Results: The level of serum sCR2 in patients with pSS was significantly lower than that in healthy control (P < 0.01). In addition, there was no correlation between patients’ age and sex in sCR2 levels. The level of serum sCR2 in the self-anti- body positive group was lower than that in the negative control group, and there was significant statistical significance (P < 0.05). In addition, the level of serum sCR2 in pSS patients showed nega- tive correlation with immunoglobulin IgG and ESR level. Conclusions: The evident decrease of se- rum sCR2 level in pSS patients has negative correlation with the levels of immunoglobulin IgG and ESR, which suggests that sCR2 may play a critical role in the pathogenesis of pSS.KeywordsPrimary Sjogren’s Syndrome, Soluble Complement Receptor 2*通讯作者。